NR 567 ADVANCED PHARMACOLOGY FOR THE AGACNP – COMPLETE PRACTICE TEST BANK
Verified Questions with Answers & Detailed Clinical Rationales | Updated 2026 | A+ Graded
TABLE OF CONTENTS
| Section | Topic | Questions |
|---------|-------|-----------|
| 1 | Exam Overview & Test Plan | — |
| 2 | Pharmacokinetics & Pharmacodynamics | Questions 1–30 |
| 3 | Neuropharmacology & Antiseizure Medications | Questions 31–60 |
| 4 | Anticoagulants, Antiplatelets & Thrombolytics | Questions 61–90 |
| 5 | Cardiovascular Pharmacology – Antiarrhythmics, Antihypertensives & Heart Failure |
Questions 91–120 |
| 6 | Endocrine Pharmacology – Diabetes, Thyroid & Adrenal Disorders | Questions 121–150 |
| 7 | Antimicrobial Therapy & Antibiotic Stewardship | Questions 151–180 |
| 8 | Respiratory & Critical Care Pharmacology | Questions 181–210 |
| 9 | Pain Management, Opioids & Substance Use Disorders | Questions 211–240 |
| 10 | Renal Pharmacology, Diuretics & Electrolyte Management | Questions 241–270 |
| 11 | Special Populations – Geriatrics, Pregnancy & Organ Failure | Questions 271–300 |
---
EXAM OVERVIEW
| Feature | Details |
|---------|---------|
,| Exam | NR 567 Advanced Pharmacology for the AGACNP |
| Course | Chamberlain University College of Nursing |
| Format | Multiple Choice, Clinical Scenarios, NGN-Style |
| Emphasis | Pharmacokinetics, Pharmacodynamics, Clinical Decision-Making, Medication
Safety |
Test Plan Weightings
| Content Area | Weight |
|--------------|--------|
| Pharmacokinetics & Pharmacodynamics | 15% |
| Neuropharmacology & Antiseizure Drugs | 12% |
| Anticoagulation & Antiplatelet Therapy | 10% |
| Cardiovascular Pharmacology | 15% |
| Endocrine Pharmacology | 12% |
| Antimicrobial Therapy & Stewardship | 10% |
| Critical Care & Respiratory Pharmacology | 8% |
| Pain Management & Opioid Pharmacology | 8% |
| Renal & Electrolyte Management | 5% |
| Special Populations & Geriatrics | 5% |
Core Domains Covered
1. Pharmacokinetics & Pharmacodynamics – Absorption, distribution, metabolism, excretion
(ADME), volume of distribution, half-life, protein binding, receptor theory, dose-response
relationships
,2. Neuropharmacology – Antiseizure medications, Parkinson's disease drugs,
psychopharmacology, benzodiazepines, NMDA receptor antagonists
3. Anticoagulation & Antiplatelet Therapy – Warfarin, DOACs, heparin, LMWH, antiplatelet
agents, reversal agents, INR monitoring
4. Cardiovascular Pharmacology – Antiarrhythmics (Vaughan Williams classification),
antihypertensives, heart failure medications, vasopressors, inotropes
5. Endocrine Pharmacology – Insulin regimens, oral antidiabetics, thyroid hormone
replacement, corticosteroids, adrenal insufficiency management
6. Antimicrobial Therapy – Antibiotic classifications (cell wall inhibitors, protein synthesis
inhibitors, fluoroquinolones), antibiotic stewardship, antifungal therapy
7. Critical Care & Respiratory Pharmacology – Vasopressors (septic shock), bronchodilators,
corticosteroids, sedation, neuromuscular blockers
8. Pain Management – Opioid pharmacology, opioid stewardship, multimodal analgesia, opioid
reversal agents
9. Renal Pharmacology – Diuretic classifications, electrolyte management, dosing adjustments in
renal failure
10. Special Populations – Geriatric pharmacotherapy, pregnancy considerations, hepatic/renal
impairment dosing
---
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Questions 1–30
---
Question 1
, Which parameter primarily determines a drug's volume of distribution (Vd)?
A) Renal clearance
B) Protein binding
C) Lipid solubility and tissue binding
D) Half-life
Correct Answer: C
Rationale: Volume of distribution (Vd) reflects how extensively a drug distributes into tissues.
Lipophilic drugs with high tissue binding have larger Vd. Protein binding affects the free fraction
but is not the primary determinant. Renal clearance and half-life are influenced by Vd but do
not determine it.
---
Question 2
A patient with severe hepatic failure will most likely have which change in drug
pharmacokinetics?
A) Increased renal excretion
B) Decreased oral absorption
C) Reduced metabolism and prolonged half-life of hepatically cleared drugs
D) Increased protein binding
Correct Answer: C
Verified Questions with Answers & Detailed Clinical Rationales | Updated 2026 | A+ Graded
TABLE OF CONTENTS
| Section | Topic | Questions |
|---------|-------|-----------|
| 1 | Exam Overview & Test Plan | — |
| 2 | Pharmacokinetics & Pharmacodynamics | Questions 1–30 |
| 3 | Neuropharmacology & Antiseizure Medications | Questions 31–60 |
| 4 | Anticoagulants, Antiplatelets & Thrombolytics | Questions 61–90 |
| 5 | Cardiovascular Pharmacology – Antiarrhythmics, Antihypertensives & Heart Failure |
Questions 91–120 |
| 6 | Endocrine Pharmacology – Diabetes, Thyroid & Adrenal Disorders | Questions 121–150 |
| 7 | Antimicrobial Therapy & Antibiotic Stewardship | Questions 151–180 |
| 8 | Respiratory & Critical Care Pharmacology | Questions 181–210 |
| 9 | Pain Management, Opioids & Substance Use Disorders | Questions 211–240 |
| 10 | Renal Pharmacology, Diuretics & Electrolyte Management | Questions 241–270 |
| 11 | Special Populations – Geriatrics, Pregnancy & Organ Failure | Questions 271–300 |
---
EXAM OVERVIEW
| Feature | Details |
|---------|---------|
,| Exam | NR 567 Advanced Pharmacology for the AGACNP |
| Course | Chamberlain University College of Nursing |
| Format | Multiple Choice, Clinical Scenarios, NGN-Style |
| Emphasis | Pharmacokinetics, Pharmacodynamics, Clinical Decision-Making, Medication
Safety |
Test Plan Weightings
| Content Area | Weight |
|--------------|--------|
| Pharmacokinetics & Pharmacodynamics | 15% |
| Neuropharmacology & Antiseizure Drugs | 12% |
| Anticoagulation & Antiplatelet Therapy | 10% |
| Cardiovascular Pharmacology | 15% |
| Endocrine Pharmacology | 12% |
| Antimicrobial Therapy & Stewardship | 10% |
| Critical Care & Respiratory Pharmacology | 8% |
| Pain Management & Opioid Pharmacology | 8% |
| Renal & Electrolyte Management | 5% |
| Special Populations & Geriatrics | 5% |
Core Domains Covered
1. Pharmacokinetics & Pharmacodynamics – Absorption, distribution, metabolism, excretion
(ADME), volume of distribution, half-life, protein binding, receptor theory, dose-response
relationships
,2. Neuropharmacology – Antiseizure medications, Parkinson's disease drugs,
psychopharmacology, benzodiazepines, NMDA receptor antagonists
3. Anticoagulation & Antiplatelet Therapy – Warfarin, DOACs, heparin, LMWH, antiplatelet
agents, reversal agents, INR monitoring
4. Cardiovascular Pharmacology – Antiarrhythmics (Vaughan Williams classification),
antihypertensives, heart failure medications, vasopressors, inotropes
5. Endocrine Pharmacology – Insulin regimens, oral antidiabetics, thyroid hormone
replacement, corticosteroids, adrenal insufficiency management
6. Antimicrobial Therapy – Antibiotic classifications (cell wall inhibitors, protein synthesis
inhibitors, fluoroquinolones), antibiotic stewardship, antifungal therapy
7. Critical Care & Respiratory Pharmacology – Vasopressors (septic shock), bronchodilators,
corticosteroids, sedation, neuromuscular blockers
8. Pain Management – Opioid pharmacology, opioid stewardship, multimodal analgesia, opioid
reversal agents
9. Renal Pharmacology – Diuretic classifications, electrolyte management, dosing adjustments in
renal failure
10. Special Populations – Geriatric pharmacotherapy, pregnancy considerations, hepatic/renal
impairment dosing
---
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS
Questions 1–30
---
Question 1
, Which parameter primarily determines a drug's volume of distribution (Vd)?
A) Renal clearance
B) Protein binding
C) Lipid solubility and tissue binding
D) Half-life
Correct Answer: C
Rationale: Volume of distribution (Vd) reflects how extensively a drug distributes into tissues.
Lipophilic drugs with high tissue binding have larger Vd. Protein binding affects the free fraction
but is not the primary determinant. Renal clearance and half-life are influenced by Vd but do
not determine it.
---
Question 2
A patient with severe hepatic failure will most likely have which change in drug
pharmacokinetics?
A) Increased renal excretion
B) Decreased oral absorption
C) Reduced metabolism and prolonged half-life of hepatically cleared drugs
D) Increased protein binding
Correct Answer: C
